EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Antoni, 2017, Bladder cancer incidence and mortality: a global overview and recent trends, Eur Urol, 71, 96, 10.1016/j.eururo.2016.06.010 Bellmunt, 2014, Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25 Babjuk, 2019, EAU guidelines on non-muscle-invasive bladder cancer, Presented at the EAU Annual Congress Barcelona. Arnhem, The Netherlands: EAU Guidelines Office Witjes, 2019, EAU guidelines on muscle-invasive and metastatic bladder cancer, Presented at the EAU Annual Congress Barcelona. Arnhem, The Netherlands: EAU Guidelines Office Vetterlein, 2017, Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology, Cancer, 123, 4346, 10.1002/cncr.30907 Robertson, 2017, Comprehensive molecular characterization of muscle-invasive bladder cancer, Cell, 171, 540, 10.1016/j.cell.2017.09.007 Choi, 2014, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, 25, 152, 10.1016/j.ccr.2014.01.009 Lindgren, 2010, Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome, Cancer Res, 70, 3463, 10.1158/0008-5472.CAN-09-4213 Damrauer, 2014, Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology, Proc Natl Acad Sci U S A, 111, 3110, 10.1073/pnas.1318376111 Ingersoll, 2018, Immunology, Immunotherapy and Translating Basic Science into the Clinic for Bladder Cancer, Bladder Cancer, 4, 429, 10.3233/BLC-180175 González Del Alba, 2019, SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018), Clin Transl Oncol, 21, 64, 10.1007/s12094-018-02001-x Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, 18, 1483, 10.1016/S1470-2045(17)30616-2 Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 389, 67, 10.1016/S0140-6736(16)32455-2 Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Comet Initiative DelphiManager, 2011–2015. http://www.comet-initiative.org/delphimanager/. Humphrey, 2016, The 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumours, Eur Urol, 70, 106, 10.1016/j.eururo.2016.02.028 Compérat, 2010, Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases, Pathology, 42, 650, 10.3109/00313025.2010.522173 Monn, 2015, Contemporary bladder cancer: variant histology may be a significant driver of disease, Urol Oncol, 33, 18, 10.1016/j.urolonc.2014.10.001 Willis, 2015, Clinical outcomes of cT1 micropapillary bladder cancer, J Urol, 193, 1129, 10.1016/j.juro.2014.09.092 Weizer, 2009, Multiple adverse histological features increase the odds of under staging T1 bladder cancer, J Urol, 182, 59, 10.1016/j.juro.2009.02.116 Black, 2009, The impact of variant histology on the outcome of bladder cancer treated with curative intent, Urol Oncol, 27, 3, 10.1016/j.urolonc.2007.07.010 Honma, 2004, Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors, Urology, 64, 744, 10.1016/j.urology.2004.05.003 Zaghloul, 1992, Soliman O, el Attar I. Postoperative radiotherapy of carcinoma in bilharzial bladder: improved disease free survival through improving local control, Int J Radiat Oncol Biol Phys, 23, 511, 10.1016/0360-3016(92)90005-3 Lewis, 2018, The role of adjuvant radiation therapy in locally advanced bladder cancer, Bladder Cancer, 4, 205, 10.3233/BLC-180163 Marzouka, 2018, A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort, Sci Rep, 8, 3737, 10.1038/s41598-018-22126-x Seiler, 2017, Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy, Eur Urol, 72, 544, 10.1016/j.eururo.2017.03.030 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Mariathasan, 2018, TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Rouprêt, 2019, European Association of Urology guidelines on upper urinary tract urothelial carcinoma, Presented at the EAU Annual Congress Barcelona. Arnhem, The Netherlands: EAU Guidelines Office Wu, 2018, Pretreatment neutrophil-lymphocyte ratio as a predictor in bladder cancer and metastatic or unresectable urothelial carcinoma patients: a pooled analysis of comparative studies, Cell Physiol Biochem, 46, 1352, 10.1159/000489152 Ojerholm, 2017, Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710, Cancer, 123, 794, 10.1002/cncr.30422 Bajorin, 1999, Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, J Clin Oncol, 17, 3173, 10.1200/JCO.1999.17.10.3173 Bellmunt, 2010, Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens, J Clin Oncol, 28, 1850, 10.1200/JCO.2009.25.4599 Sonpavde, 2016, Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma, J Urol, 195, 277, 10.1016/j.juro.2015.07.111 Zhang, 2016, Prognostic role of lactate dehydrogenase expression in urologic cancers: a systematic review and meta-analysis, Oncol Res Treat, 39, 592, 10.1159/000449138 Hussain, 2015, Collaboration between surgeons and medical oncologists and outcomes for patients with stage III colon cancer, J Oncol Pract, 11, 10.1200/JOP.2014.003293 Cook, 2015, Exploration of the role of specialist nurses in the care of women with gynaecological cancer: a systematic review, J Clin Nurs, 24, 683, 10.1111/jocn.12675 Choudhury, 2011, Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer, J Clin Oncol, 29, 733, 10.1200/JCO.2010.31.5721 Coppin, 1996, Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 14, 2901, 10.1200/JCO.1996.14.11.2901 Hoskin, 2010, Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma, J Clin Oncol, 28, 4912, 10.1200/JCO.2010.28.4950 James, 2012, Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, 366, 1477, 10.1056/NEJMoa1106106 Koga, 2009, Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study, BJU Int, 104, 189, 10.1111/j.1464-410X.2008.08297.x Tunio, 2012, Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience, Int J Radiat Oncol Biol Phys, 82, e457, 10.1016/j.ijrobp.2011.05.051 Collins, 2018, A review of plan library approaches in adaptive radiotherapy of bladder cancer, Acta Oncol, 57, 566, 10.1080/0284186X.2017.1420908 Bos, 2014, Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review, J Contemp Brachytherapy, 6, 191, 10.5114/jcb.2014.43777 Whalley, 2015, Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer, Radiat Oncol, 10, 205, 10.1186/s13014-015-0499-0 Weichselbaum, 2018, The 46th David A. Karnofsky Memorial Award lecture: oligometastasis—from conception to treatment, J Clin Oncol, 36, 3240, 10.1200/JCO.18.00847 Kim, 2015, Pulmonary metastasectomy could prolong overall survival in select cases of metastatic urinary tract cancer, Clin Genitourin Cancer, 13, e297, 10.1016/j.clgc.2015.04.013 Pastorino, 1997, Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases, J Thorac Cardiovasc Surg, 113, 37, 10.1016/S0022-5223(97)70397-0 Tanvetyanon, 2008, Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis, J Clin Oncol, 26, 1142, 10.1200/JCO.2007.14.2091 von der Maase, 2005, Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer, J Clin Oncol, 23, 4602, 10.1200/JCO.2005.07.757 Galsky, 2013, Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy, Cancer, 119, 3012, 10.1002/cncr.28146 Lehmann, 2009, Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05), Eur Urol, 55, 1293, 10.1016/j.eururo.2008.11.039 Abe, 2007, Impact of multimodal treatment on survival in patients with metastatic urothelial cancer, Eur Urol, 52, 1106, 10.1016/j.eururo.2007.02.052 Abufaraj, 2018, The role of surgery in metastatic bladder cancer: a systematic review, Eur Urol, 73, 543, 10.1016/j.eururo.2017.09.030 Kibel, 2009, Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma, J Clin Oncol, 27, 4314, 10.1200/JCO.2008.20.6722 Lu, 2012, Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis, Eur J Radiol, 81, 2411, 10.1016/j.ejrad.2011.07.018 Bagheri, 2017, Advances in medical imaging for the diagnosis and management of common genitourinary cancers, Urol Oncol, 35, 473, 10.1016/j.urolonc.2017.04.014 Leow, 2014, Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials, Eur Urol, 66, 42, 10.1016/j.eururo.2013.08.033 Nishino, 2017, Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions, Clin Cancer Res, 23, 4671, 10.1158/1078-0432.CCR-17-0114 Powles, 2018, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 391, 748, 10.1016/S0140-6736(17)33297-X Powles, 2017, Immune Checkpoint inhibition in metastatic urothelial cancer, Eur Urol, 72, 477, 10.1016/j.eururo.2017.03.047 Szabados, 2018, Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer, Eur Urol, 73, 149, 10.1016/j.eururo.2017.08.022 Giannarini, 2010, Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?, Eur Urol, 58, 486, 10.1016/j.eururo.2010.05.041 Volkmer, 2009, Oncological followup after radical cystectomy for bladder cancer—is there any benefit?, J Urol, 181 Huguet, 2013, Follow-up after radical cystectomy based on patterns of tumour recurrence and its risk factors, Acta Urol Esp, 37, 376, 10.1016/j.acuro.2013.01.005 Chan, 2016, Urethral recurrence after cystectomy: current preventative measures, diagnosis and management, BJU Int, 117, 563, 10.1111/bju.13370 Pieras, 2003, Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation, Eur Urol, 44, 222, 10.1016/S0302-2838(03)00258-6 Giacalone, 2017, Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience, Eur Urol, 71, 952, 10.1016/j.eururo.2016.12.020 Nieuwenhuijzen, 2008, Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions, Eur Urol, 53, 834, 10.1016/j.eururo.2007.09.008